China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabie...( DALIAN China Jan. 21 Asia-FirstCa...)

DALIAN, China, Jan. 21 /PRNewswire-Asia-FirstCall/ -- China Bio-Immunity Corporation (OTC Bulletin Board: CHHB) (China Bio-Immunity" or "the Company"), a China-based company that develops, produces, manufactures and markets proprietary vaccine-based prophylactics and therapeutics exclusively within China, today announced that it has initiated a voluntary nationwide recall of the unused lots of its rabies vaccines. The lots are being voluntarily recalled as a precaution following a notification issued by China's State Food and Drug Administration ("SFDA") of the possibility of a flaw in the Company's rabies vaccines.

On Monday, January 12, 2009, following an inspection conducted by the National Institute for the Control of Pharmaceutical and Biological Products ("NICPBP") on an approved sample of rabies vaccine submitted for batch release by the Company's operating subsidiary, Dalian Jingang-Andi Bio-Products Co., Ltd. ("Dalian JGAD"), the SFDA issued a notification on its website that there may be the possibility of a flaw in the rabies vaccines manufactured by Dalian JGAD. Preliminary results of the inspection conducted by the NICPBP have suggested the possibility of a flaw in the Company's rabies vaccines.

As of today, the National Center for Adverse Drug Reaction Monitoring, China, an affiliate of the SFDA, has not received any complaints about the Company's rabies vaccine. In conjunction with its inspections, the SFDA has requested the Liaoning Provincial Food and Drug Administration enhance its monitoring of the Company's vaccines, and has ordered a temporary shut down of the Company's production facilities. Additionally, the local SFDA has also initiated further investigation on this issue.

Mr. Quanfeng Wang, Chief Executive Officer of China Bio-Immunity, commented, "The safety and quality of our products is always our highest priority. Though the SFDA has not yet reached a conclu
'/>"/>